(NASDAQ: BBNX) Beta Bionics's forecast annual revenue growth rate of 28.25% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.2%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Beta Bionics's revenue in 2026 is $119,013,000.On average, 12 Wall Street analysts forecast BBNX's revenue for 2026 to be $6,117,247,877, with the lowest BBNX revenue forecast at $5,775,776,145, and the highest BBNX revenue forecast at $6,391,684,974. On average, 12 Wall Street analysts forecast BBNX's revenue for 2027 to be $8,239,411,460, with the lowest BBNX revenue forecast at $7,151,560,804, and the highest BBNX revenue forecast at $9,164,399,446.
In 2028, BBNX is forecast to generate $11,543,454,147 in revenue, with the lowest revenue forecast at $10,101,084,750 and the highest revenue forecast at $13,226,968,272.